CALD1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
HeLa
Human
Cervix
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
CALD1_HUMAN, CDM, Caldesmon, Caldesmon 1, Caldesmon 1 Isoform 1, Caldesmon 1 Isoform 2, Caldesmon 1 Isoform 3, Caldesmon 1 Isoform 4, Caldesmon 1 Isoform 5, H CAD, L CAD, MGC21352, NAG22
CALD1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
HeLa
Human
Cervix
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 1.
Adenocarcinoma
CALD1
Knockout
CRISPR technology
Sanger Sequencing, Western blot
Homozygous
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
EU: 2 US: 2
Adherent
Female
Ambient - Can Ship with Ice
-20°C
-20°C
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
Caldesmon also known as CDM CALD1 and h-caldesmon is a cytoskeletal protein with a molecular mass of approximately 93 to 120 kDa. This protein expresses itself abundantly in smooth muscle tissues yet it can also be found in non-muscle cells like fibroblasts and endothelial cells. Researchers often use specific caldesmon antibodies in immunohistochemistry allowing them to label various cellular components and providing insights into tissue composition. Due to its presence in muscle tissues caldesmon is essential for understanding muscle physiology and pathology.
Caldesmon interacts with actin and myosin to regulate actomyosin contractility. This protein plays a critical role in controlling the contraction and relaxation processes in smooth muscle cells. Caldesmon forms part of a complex that includes calmodulin and tropomyosin enhancing its ability to stabilize actin filaments. It functions by inhibiting the ATPase activity of myosin therefore influencing cellular motility and shape change mechanisms. Researchers continually study caldesmon to comprehend its interactome and its significance within the larger cellular structure.
Caldesmon participates in the regulation of the cytoskeletal dynamics vital for cell motility and structural integrity. In particular it is an important component of the contraction-relaxation cycle pathway in smooth muscle tissues. This protein has connections with pathways involving RhoA-Rho kinase where caldesmon modulates the phosphorylation levels influencing muscle contraction. Additionally proteins like tropomyosin and calmodulin modulate its activity especially under calcium-calmodulin-dependent pathways which further elucidates its regulatory importance.
Caldesmon has associations with conditions like certain types of cancers and cardiovascular diseases. Its expression levels and distribution provide valuable information in identifying smooth muscle tumors and other pathological conditions. In oncology for example h-caldesmon serves as a marker to distinguish leiomyosarcomas from other tumors. Moreover due to its involvement in smooth muscle contractility caldesmon links with proteins such as calmodulin and tropomyosin in diseases where abnormal contraction and cellular motility play significant roles. Understanding these connections is important for developing targeted treatments and improving diagnostic accuracy.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Wild-type HeLa cell lysate (20 μg)
Lane 2: CALD1 knockout HeLa cell lysate (20 μg)
Lane 3: NIH/3T3 cell lysate (20 μg)
Lane 4: HEK-293 cell lysate (20 μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-Caldesmon/CDM antibody [SP226] ab183339 observed at 75 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 36 kDa.
Anti-Caldesmon/CDM antibody [SP226] ab183339 Anti-Caldesmon/CDM antibody [SP226] was shown to specifically react with Caldesmon/CDM in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human CALD1 (Caldesmon/CDM) knockout HeLa cell line ab265026 (knockout cell lysate ab257375) was used. Wild-type and Caldesmon/CDM knockout samples were subjected to SDS-PAGE. Anti-Caldesmon/CDM antibody [SP226] ab183339 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Caldesmon/CDM antibody [SP226] (Anti-Caldesmon/CDM antibody [SP226] ab183339) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CALD1 knockout HeLa cell lysate at 20 µg
Lane 3: NIH/3T3 cell lysate at 20 µg
Lane 4: HEK-293 cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/10000 dilution
Predicted band size: 93 kDa
Observed band size: 75 kDa
This data was developed using the same antibody clone in a different buffer formulation (Anti-Caldesmon/CDM antibody [SP226] ab183339).
Lanes 1-4: Merged signal (red and green). Green - Anti-Caldesmon/CDM antibody [SP226] ab183339 observed at 75 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 36 kDa.
Anti-Caldesmon/CDM antibody [SP226] ab183339 Anti-Caldesmon/CDM antibody [SP226] was shown to specifically react with Caldesmon/CDM in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human CALD1 (Caldesmon/CDM) knockout HeLa cell line ab265026 (knockout cell lysate ab257375) was used. Wild-type and Caldesmon/CDM knockout samples were subjected to SDS-PAGE. Anti-Caldesmon/CDM antibody [SP226] ab183339 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
Lane 1: Wild-type HeLa cell lysate (20 μg)
Lane 2: CALD1 knockout HeLa cell lysate (20 μg)
Lane 3: NIH/3T3 cell lysate (20 μg)
Lane 4: HEK-293 cell lysate (20 μg)
Lanes 1-4: Merged signal (red and green). Green - Anti-Caldesmon/CDM antibody [E89] ab32330 observed at 75 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 36 kDa.
Anti-Caldesmon/CDM antibody [E89] ab32330 Anti-Caldesmon/CDM antibody [E89] was shown to specifically react with Caldesmon/CDM in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human CALD1 (Caldesmon/CDM) knockout HeLa cell line ab265026 (knockout cell lysate ab257375) was used. Wild-type and Caldesmon/CDM knockout samples were subjected to SDS-PAGE. Anti-Caldesmon/CDM antibody [E89] ab32330 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-Caldesmon/CDM antibody [E89] (Anti-Caldesmon/CDM antibody [E89] ab32330) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: CALD1 knockout HeLa cell lysate at 20 µg
Lane 3: NIH/3T3 cell lysate at 20 µg
Lane 4: HEK-293 cell lysate at 20 µg
All lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/10000 dilution
Predicted band size: 93 kDa
Observed band size: 75 kDa
This data was developed using the same antibody clone in a different buffer formulation (Anti-Caldesmon/CDM antibody [E89] ab32330).
Lanes 1-4: Merged signal (red and green). Green - Anti-Caldesmon/CDM antibody [E89] ab32330 observed at 75 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 36 kDa.
Anti-Caldesmon/CDM antibody [E89] ab32330 Anti-Caldesmon/CDM antibody [E89] was shown to specifically react with Caldesmon/CDM in wild-type HeLa cells. Loss of signal was observed when knockout cell line Human CALD1 (Caldesmon/CDM) knockout HeLa cell line ab265026 (knockout cell lysate ab257375) was used. Wild-type and Caldesmon/CDM knockout samples were subjected to SDS-PAGE. Anti-Caldesmon/CDM antibody [E89] ab32330 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
Homozygous: 1 bp insertion in exon 1
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com